Why the study?
Do biomarkers such as D-Dimer, soluble P-selectin, coagulation factor VIII, inflammatory markers, and thrombin generation help predict primary or recurrent VTE and optimize clinical management?
Do biomarkers such as D-Dimer, soluble P-selectin, coagulation factor VIII, inflammatory markers, and thrombin generation help predict primary or recurrent VTE and optimize clinical management?
Biomarkers such as D-Dimer, soluble P-selectin, and others may play a role in predicting primary and recurrent VTE and optimizing clinical management.
Answers are grounded in this paper and cite their sources.
Biomarker data for VTE risk remain preliminary; leaves open prospective validation before clinical integration.
Venous thromboembolism (VTE) represents a significant health concern because of its high morbidity and mortality and is moreover characterized by high rates of recurrence. It would be useful to know biomarkers that enable early identification of patients at high or low risk of primary and recurrent VTE. Various established and novel biomarkers associated with VTE have been investigated with regard to their potential for predicting primary or recurrent VTE, for facilitating the diagnosis and for optimizing the clinical management of VTE. In this review, data on selected biomarkers (D-Dimer, soluble P-selectin, coagulation factor VIII, inflammatory markers and thrombin generation) having procoagulant properties or reflecting a prothrombotic state are summarized, and their role in clinical application is discussed.
No takes yet. Share an insight, caveat, or question.
Pabinger et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: